FN2 Earnings Intelligence
Neurocrine Biosciences, Inc. ratios (quarterly)
Neurocrine Biosciences, Inc. (NBIX) Ratios (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $264 | $340.2 | $266.5 | $332.4 | $641.5 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $687.5 | $794.9 | $814.5 | $959 | $1,122.7 |
| % Growth | - | - | - | - | - |
| Gross Profit | $676.2 | $780.9 | $800.7 | - | - |
| % Margin | 98.4% | 98.2% | 98.3% | - | - |
| EBITDA | - | - | $200.6 | - | - |
| % Margin | - | - | 24.6% | - | - |
| Net Income | $107.5 | $209.5 | $197.9 | $144.4 | $206.5 |
| % Margin | 15.6% | 26.4% | 24.3% | 15.1% | 18.4% |
| Diluted EPS | $1.06 | $2.04 | $1.91 | $1.39 | $1.96 |
| % Growth | - | - | - | - | - |
| Operating Cash Flow | - | - | $145.8 | - | - |
| CapEx | - | - | $9.1 | - | - |
| Free Cash Flow | - | - | $136.7 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 |
|---|---|---|---|---|---|
| Revenue | $687.5 | $794.9 | $814.5 | $959 | $1,122.7 |
| Gross Profit | $676.2 | $780.9 | $800.7 | - | - |
| EBITDA | - | - | $200.6 | - | - |
| Net Income | $107.5 | $209.5 | $197.9 | $144.4 | $206.5 |
| Diluted EPS | $1.06 | $2.04 | $1.91 | $1.39 | $1.96 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $264 | $340.2 | $266.5 | $332.4 | $641.5 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | - | $145.8 | - | - |
| Capital Expenditure | - | - | $9.1 | - | - |
| Free Cash Flow | - | - | $136.7 | - | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 98.4% | 98.2% | 98.3% | - | - |
| EBITDA Margin | - | - | 24.6% | - | - |
| Net Margin | 15.6% | 26.4% | 24.3% | 15.1% | 18.4% |
| FCF Margin | - | - | 16.8% | - | - |
| Diluted EPS Growth | - | - | - | - | - |
Get the NBIX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.